Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guido Steiner

Showing results (21-30 of 35) with videos related to

Pageof 4
Sort By:
Molecular Pharmaceutics|July 30, 2025
Ocular Kinetics, Distribution, and Effects of Human VEGF Isoforms 121 and 165: Implications for Therapeutic InterventionAntonello Caruso, Judith J Mittag, Stefan Dengl, et al.
Hepatology Communications|June 4, 2020
Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-α in Woodchucks Chronically Infected With Woodchuck Hepatitis VirusStephan Menne, Steffen Wildum, Guido Steiner, et al.
Journal of Pharmacological and Toxicological Methods|May 29, 2016
Human ex-vivo action potential model for pro-arrhythmia risk assessmentGuy Page, Phachareeya Ratchada, Yannick Miron, et al.
Pharmaceutics|December 23, 2022
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of BiotherapeuticsMichel Siegel, Guido Steiner, Linnea C Franssen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 17, 2026
Transient prophylactic immunosuppression with abatacept or dasatinib prevents immune responses in AAV gene transferRebecca Xicluna, Kentaro Yamada, Miguel Gonzalez-Visiedos, et al.
Clinical Pharmacology and Therapeutics|June 17, 2026
Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple MyelomaThomas E Kraft, Estelle Marrer-Berger, Sara Belli, et al.
Frontiers in Immunology|June 9, 2022
Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis BSteffen Wildum, Kyle E Korolowicz, Manasa Suresh, et al.
Scientific Reports|January 3, 2025
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapyRachael A Potter, Ida H Moeller, Sohrab Khan, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|April 28, 2011
Characterization of post-surgical alterations in the bile duct-cannulated ratDalila Bachir-Cherif, Denise Blum, Annamaria Braendli-Baiocco, et al.
Mabs|November 17, 2022
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic miceJerome Egli, Stefan Heiler, Felix Weber, et al.
Pageof 4

Showing results (21-30 of 35) with videos related to

Sort By:
Pageof 4
Molecular Pharmaceutics|July 30, 2025
Ocular Kinetics, Distribution, and Effects of Human VEGF Isoforms 121 and 165: Implications for Therapeutic InterventionAntonello Caruso, Judith J Mittag, Stefan Dengl, et al.
Hepatology Communications|June 4, 2020
Efficacy of an Inhibitor of Hepatitis B Virus Expression in Combination With Entecavir and Interferon-α in Woodchucks Chronically Infected With Woodchuck Hepatitis VirusStephan Menne, Steffen Wildum, Guido Steiner, et al.
Journal of Pharmacological and Toxicological Methods|May 29, 2016
Human ex-vivo action potential model for pro-arrhythmia risk assessmentGuy Page, Phachareeya Ratchada, Yannick Miron, et al.
Pharmaceutics|December 23, 2022
Validation of a Dendritic Cell and CD4+ T Cell Restimulation Assay Contributing to the Immunogenicity Risk Evaluation of BiotherapeuticsMichel Siegel, Guido Steiner, Linnea C Franssen, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|April 17, 2026
Transient prophylactic immunosuppression with abatacept or dasatinib prevents immune responses in AAV gene transferRebecca Xicluna, Kentaro Yamada, Miguel Gonzalez-Visiedos, et al.
Clinical Pharmacology and Therapeutics|June 17, 2026
Patient-Centric First-in-Human Dose Selection: An Ex Vivo Minimal Anticipated Biological Effect Level Approach for T-Cell Engagers in Multiple MyelomaThomas E Kraft, Estelle Marrer-Berger, Sara Belli, et al.
Frontiers in Immunology|June 9, 2022
Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis BSteffen Wildum, Kyle E Korolowicz, Manasa Suresh, et al.
Scientific Reports|January 3, 2025
Immunologic investigations into transgene directed immune-mediated myositis following delandistrogene moxeparvovec gene therapyRachael A Potter, Ida H Moeller, Sohrab Khan, et al.
Xenobiotica; the Fate of Foreign Compounds in Biological Systems|April 28, 2011
Characterization of post-surgical alterations in the bile duct-cannulated ratDalila Bachir-Cherif, Denise Blum, Annamaria Braendli-Baiocco, et al.
Mabs|November 17, 2022
Enhanced immunogenic potential of cancer immunotherapy antibodies in human IgG1 transgenic miceJerome Egli, Stefan Heiler, Felix Weber, et al.
Pageof 4